Compare

Cosmo Pharmaceuticals N.V./Fr. COPN

1D1W1M3M6MYTD1Y5YMAX

About Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company based in Lainate, Italy, focusing on the development and manufacturing of products for specific gastrointestinal diseases. The company's core business involves oral therapies, particularly for conditions such as inflammatory bowel disease and colon cancer. Notable products include Lialda/Mezavant, a treatment for ulcerative colitis, and Eleview, a medical device used in endoscopic procedures. Cosmo Pharmaceuticals leverages proprietary drug delivery technologies to enhance treatment efficacy and patient compliance. While headquartered in Italy, it operates primarily within the European market and maintains a strategic partnership network to expand its global reach.
Ticker
Fr. COPN
Sector
Health
Primary listing
XSWX
Employees
365
Headquarters
Dublin, Ireland
Website
www.cosmohealthconfidence.com

COPN Metrics

BasicAdvanced
CHF 987M
-
-CHF 0.36
1.48
CHF 1.92
3.32%

Bulls say / Bears say

Recurring revenue rose 18% in H1 2026, with Winlevi up 38%, Lialda up 35% and CDMO up 14%. Growth across several businesses gives Cosmo a stronger base than relying on a single product. (Newsfile Corp.)
Cosmo completed Phase III testing of clascoterone 5% for hair loss, reporting positive 12-month efficacy and safety data. It is preparing US and European filings for 2027, offering a potential new growth driver if regulators approve it. (Newsfile Corp.)
Rifamycin gel met its Phase II primary endpoint in distal ulcerative colitis, with remission in 46.2% of treated patients versus 14.3% on placebo. The result supports further development for an unmet treatment need, though it is not yet evidence of commercial success. (Seeking Alpha)
Recurring revenue growth has not yet lifted total revenue or profits: H1 revenue slipped to €50.2 million from €51.7 million, while Cosmo reported a wider €4.7 million net loss. Continued growth will need to translate into better reported earnings. (Newsfile Corp., StockTitan)
GI Genius revenue was lower in H1 because production scale-up and the Module 300 rollout shifted more sales into the second half. That makes delivery of the full-year outlook more dependent on a timely ramp-up. (Newsfile Corp.)
A recent valuation analysis says the shares may be priced for perfection after a 68.7% rise over three years. With rifamycin still at Phase II, delays or weaker-than-hoped commercial uptake could disappoint investors already counting on pipeline value. (Yahoo Finance, Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.